Adoption of elective medical procedures is increasing dramatically worldwide. Women are largely driving this trend, which is creating an emerging demand for nonsurgical gynecologic treatments. Despite the growing demand, there is a surprisingly limited number of safe and effective technologies specifically designed for female conditions. Now, there is a company that is helping women’s health and wellness come into its own – Viveve.
What sets us apart?
Internationally Patented Technology
Our passion drives innovation! We are proud to develop platform technologies that improve women’s health and overall well-being, while adhering to the highest scientific and ethical standards. Sustained tissue tightening and strengthening requires substantial heating at the appropriate depth in tissue. Only the Viveve® System utilizes cryogen-cooled monopolar radiofrequency (CMRF) to uniformly deliver gentle volumetric heating while cooling delicate surface tissue. Because of our unique technology, robust neocollagenesis is stimulated by one 30-minute in-office Geneveve by Viveve session.
Robust Clinical Science
The Geneveve treatment has been tested in three prospective clinical trials: one in the U.S., one in Japan and a large, multi-center randomized, placebo-controlled multi-national clinical trial. The goal of assessing the safety, effectiveness and meaningful benefit of the treatment was successfully achieved. In all trials, statistically significant and sustained results were found.
Viveve External Research Program
Viveve’s External Research Program (ERP) supports a global network of investigator-initiated research focusing on the cultivation of elective procedures and leading-edge medical device technologies. The program fosters investigative research with the goal of improving the quality of patient care and clinical outcomes.
Enthusiastic Acceptance Worldwide
Viveve specializes in low-risk high reward treatments for both patients and healthcare practitioners. The Viveve System is available in many countries around the world. To find out where click here.